Skip to main content
Top
Published in: Trials 1/2022

Open Access 01-12-2022 | Care | Methodology

Development and evaluation of rapid data-enabled access to routine clinical information to enhance early recruitment to the national clinical platform trial of COVID-19 community treatments

Authors: Caroline Cake, Emma Ogburn, Heather Pinches, Garry Coleman, David Seymour, Fran Woodard, Sinduja Manohar, Marjia Monsur, Martin Landray, Gaynor Dalton, Andrew D. Morris, Patrick F. Chinnery, F. D. Richard Hobbs, Christopher Butler, UK COVID-19 National Core Studies Consortium

Published in: Trials | Issue 1/2022

Login to get access

Abstract

Background

The COVID-19 pandemic has presented unique challenges for rapidly designing, initiating, and delivering therapeutic clinical trials. PRINCIPLE (Platform Randomised Trial of Treatments in the Community for Epidemic and Pandemic Illnesses) is the UK national platform investigating repurposed therapies for COVID-19 treatment of older people in the community at high risk of complications. Standard methods of patient recruitment were failing to meet the required pace and scale of enrolment.
This paper describes the development and appraisal of a near real-time, data-driven, ethical approach for enhancing recruitment in community care by contacting people with a recent COVID-19 positive test result from the central NHS Test and Trace service within approximately 24–48 h of their test result.

Methods

A multi-disciplinary team was formed to solve the technical, ethical, public perception, logistical and information governance issues required to provide a near-real time (approximately within 24–48 h of receiving a positive test) feed of potential trial participants from test result data to the research team. PRINCIPLE was also given unique access to the Summary Care Record (SCR) to ensure safe prescribing, and to enable the trial team to quickly and safely bring consented patients into the trial. A survey of the public was used to understand public perceptions of the use of test data for this proposed methodology.

Results

Prior to establishing the data service, PRINCIPLE registered on average 87 participants per week. This increased by up to 87 additional people registered per week from the test data, contributing to an increase from 1013 recruits to PRINCIPLE at the start of October 2020 to 2802 recruits by 20 December 2020.
Whilst procedural caveats were identified by the public consultation, out of 2639 people contacted by PRINCIPLE following a positive test result, no one raised a concern about being approached.

Conclusions

This paper describes a novel approach to using near-real time NHS operational data to recruit community-based patients within a few days of presentation with acute illness.
This approach increased recruitment and reduced time between positive test and randomisation, allowing more rapid evaluation of treatments and increased safety for participants. End-to-end public and patient involvement in the design of the approach provided evidence to inform information governance decisions.

Trial registration

PRINCIPLE is funded by UK Research and Innovation and the Department of Health and Social Care through the National Institute for Health Research.
EudraCT number: 2020-001209-22. 26/03/2020
ISRCTN registry: ISRCTN86534580. 20/03/2020
REC number: 20/SC/058
IRAS number: 281958
Appendix
Available only for authorised users
Literature
6.
go back to reference Landray MJ, REVEAL Collaborative Group, et al. Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL) —a large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics. Am Heart J. 2017;187:182–90, ISSN 0002-8703. https://doi.org/10.1016/j.ahj.2017.02.021.CrossRefPubMedPubMedCentral Landray MJ, REVEAL Collaborative Group, et al. Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL) —a large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics. Am Heart J. 2017;187:182–90, ISSN 0002-8703. https://​doi.​org/​10.​1016/​j.​ahj.​2017.​02.​021.CrossRefPubMedPubMedCentral
Metadata
Title
Development and evaluation of rapid data-enabled access to routine clinical information to enhance early recruitment to the national clinical platform trial of COVID-19 community treatments
Authors
Caroline Cake
Emma Ogburn
Heather Pinches
Garry Coleman
David Seymour
Fran Woodard
Sinduja Manohar
Marjia Monsur
Martin Landray
Gaynor Dalton
Andrew D. Morris
Patrick F. Chinnery
F. D. Richard Hobbs
Christopher Butler
UK COVID-19 National Core Studies Consortium
Publication date
01-12-2022
Publisher
BioMed Central
Keywords
Care
COVID-19
Published in
Trials / Issue 1/2022
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-021-05965-4

Other articles of this Issue 1/2022

Trials 1/2022 Go to the issue